Please assess the completion status of the following clinical trial:

Trial Title: The HPV-SAVE Study Team: HPV Screening and Vaccine Evaluation in Men Who Have Sex With Men

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males, aged ≥18 years at baseline;~* Identify as a man who has sex with a men (MSM);~* HIV-positive; laboratory documentation of HIV-1 infection;~* For those on combination antiretroviral therapy (cART), the participant must be on a stable regimen;~* An ability to give informed consent;~* An ability to attend clinic for follow-up, including possible HRA and biopsy;~* AIN-2 or -3 found on biopsy of anal canal lesion(s);~* Willingness to be randomized to undergo ablative therapy or active surveillance.~Exclusion Criteria:~* Current or prior history of cancer of the anogenital regions (e.g. penile, anal, or rectal).;~* Previous treatment of high grade dysplasia;

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Ablative therapy (Type: EXPERIMENTAL): Ablative therapy involving electrocautery (EC) will occur for participants with AIN-2 and AIN-3. The Hyfrecator ® 2000 Electrosurgical System will be used for EC therapy.
- Active Surveillance (Type: ACTIVE_COMPARATOR): The control arm includes active surveillance with observation alone; no treatment in AIN-2 and -3.

Based on this trial design, predict the completion outcome and termination type (if applicable).